Evolution or revolution?
At ESCRS 2025, top minds in glaucoma—Dr. Sev Teymoorian, Dr. Kevin Gillmann, Prof. Henny Beckers, Prof. Ike Ahmed and Dr. Imran Masood—unpack what makes the Glaukos iStent infinite® such a game-changer in MIGS.
From boosting patient adherence to delivering next-level outcomes, this session revealed why a third stent, smarter injector design and proven safety profile1 are raising the bar in glaucoma treatment. Could this be the next big leap in glaucoma care?
Find the full booth talk at https://youtu.be/baTe9fgEwYI?si=O7sLJet7aJzip567 and visit https://www.glaukos.com/ for more information.
At ESCRS 2025, leading experts—Dr. Sev Teymoorian, Dr. Kevin Gillmann, Prof. Henny Beckers, Prof. Ike Ahmed and Dr. Imran Masood—came together at a Glaukos symposium to explore how the iStent infinite® is redefining the treatment landscape for glaucoma.
From improving patient adherence to advancing MIGS outcomes, this session dives into the data, surgical insights and real-world impact of this next-generation device. Learn why the addition of a third stent, refined injector design and proven safety profile1 are setting new standards in glaucoma management.
Watch the full video to discover how the iStent infinite® is changing the conversation from incremental evolution to potential revolution. Learn more at https://www.glaukos.com/
Stent infinite® IMPORTANT SAFETY INFORMATION:
https://glaukos.showpad.com/share/whEAZgd28rRkhzQOJYyrg
1-Sarkisian Jr, Steven R., et al. “Effectiveness and safety of iStent infinite trabecular micro-bypass for uncontrolled glaucoma.” Journal of glaucoma 32.1 (2023): 9-18.
Glaukos® and iStent infinite® are registered trademarks of Glaukos Corporation.
All rights reserved. ©2025. PM-EU-0396
This content is intended exclusively for healthcare professionals and eye care practitioners. It is not intended for the general public. Products or therapies discussed may not be registered or approved in all countries.
Speakers are paid consultants of Glaukos.
